NCT00010049 is a Phase 1, PHASE2 clinical trial of imatinib mesylate in Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT00010049?

NCT00010049 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT00010049?

Interventions in NCT00010049: imatinib mesylate.

What condition does NCT00010049 study?

NCT00010049 studies Brain and Central Nervous System Tumors.

Is NCT00010049 still recruiting?

NCT00010049 is currently completed. Last updated 27 June 2018.

Last reviewed 2018-06-27 · How we verify

NCT00010049

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Completed Phase 1, PHASE2 Last updated 27 June 2018

What this trial tests

Phase 1, PHASE2 trial testing imatinib mesylate in Brain and Central Nervous System Tumors in 105 participants. Completed in 15 August 2006.

Timeline

27 February 2001

Primary endpoint
17 March 2005

15 August 2006

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Design	parallel
Primary purpose	treatment
Enrollment	105
Start date	27 February 2001
Primary completion	17 March 2005
Estimated completion	15 August 2006
Sites	11 locations across United States

Drugs / interventions tested

imatinib mesylate — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for recurrent glioma and meningioma. PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate in treating patients who have progressive, recurrent, or unresectable malignant glioma or meningioma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting protein kinases in central nervous system disorders.
Chico LK, Van Eldik LJ, Watterson DM. · · 2009 · cited 197× · PMID 19876042 · DOI 10.1038/nrd2999
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.
Di Cintio F, Dal Bo M, Baboci L, De Mattia E, et al · · 2020 · cited 28× · PMID 33324155 · DOI 10.3389/fnins.2020.603647
Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas.
Konovalov N, Timonin S, Asyutin D, Raevskiy M, et al · · 2022 · cited 4× · PMID 35387112 · DOI 10.3389/fonc.2022.837570

Verify or expand the search:

Other trials of imatinib mesylate

Trials testing the same drug.

NCT01742299 — Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benef · Phase 4 · active not recruiting
NCT00867113 — Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Phase 2 · completed
NCT00401024 — Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma · Phase 1 · completed
NCT00483366 — Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors · Phase 1 · completed
NCT00323063 — Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer · Phase 2 · terminated

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00010049 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 27 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00010049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing